Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifestyle intervention and rifaximin for metabolic associated fatty liver disease
ChiCTR2100046116Phase 4Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rifaximin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Alanine aminotransferase and Regression degree of fatty liver by B-ultrasound. Started May 2021; status: recruiting.
02
Drugs
rifaximin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2100046116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046116.